Mind Medicine (MindMed) Inc

Mind Medicine (MindMed) Inc

  • Price (EUR)3.63
  • Today's Change0.18 / 5.22%
  • Shares traded1.16k
  • 1 Year change-76.09%
  • Beta--
Data delayed at least 15 minutes, as of Feb 08 2023 17:24 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Mind Medicine (MindMed) Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company is developing a pipeline of drug candidates, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, including lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA) and zolunicant, or 18-methoxycoronaridine (MC), a congener of ibogaine. The Company’s subsidiaries include Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-92.07m
  • Incorporated2010
  • Employees50.00
  • Location
    Mind Medicine (MindMed) Inc1166 Alberni Steet, Suite 1604VANCOUVER V6E 3Z3CanadaCAN
  • Phone+1 (203) 648-5275
  • Fax+1 (888) 848-3972
  • Websitehttps://mindmed.co/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.